ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission"

  • Abstract Number: 2107 • 2012 ACR/ARHP Annual Meeting

    Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy

    Matthias Witt1, Felix Mueller2, Axel Nigg2, Christiane Reindl3, Hendrik Schulze-Koops2 and Mathias Grunke2, 1Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 2Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 3Division for Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany

    Background/Purpose: Treat-to-target is a key principle in rheumatoid arthritis. Composite scores such as the DAS-28 help to monitor disease activity and response to therapy. However,…
  • Abstract Number: 1335 • 2012 ACR/ARHP Annual Meeting

    Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy

    Patrick Durez1, Geneviève Depresseux2, Marie Avaux2, Adrien Nzeusseu Toukap3, Bernard Lauwerys3, Laurent Meric de Bellefon2, Maria S. Stoenoiu2 and Frédéric A. Houssiau4, 1Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, 3Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 4Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Tocilizumab (TCZ), as monotherapy and in combination with methotrexate (MTX), has been shown to be efficacious for rheumatoid arthritis patients with insufficient response to…
  • Abstract Number: 1043 • 2012 ACR/ARHP Annual Meeting

    Assessment of Rheumatoid Arthritis Disease Activity by Power Doppler Ultrasonography: Association with Routine Clinical Indices and Its Usefulness in Detecting Remission

    Hiroaki Taguchi, Kazuo Nishi, Takeo Kudo and Yutaka Okano, Division of Rheumatology, Department of Medicine, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan

    Background/Purpose: Power Doppler ultrasonography (PDUS) is sensitive for detecting synovitis in patients with rheumatoid arthritis (RA).  We aimed to clarify the association of PDUS findings…
  • Abstract Number: 1049 • 2012 ACR/ARHP Annual Meeting

    The Prevalence of the Ultrasonographic Positive Power Doppler Synovitis Is High and Predicts the Risk of Relapse and Structural Progression in Rheumatoid Arthritis in Clinical Remission: A Systematic Literature Review and Meta Analysis

    Huong Nguyen1, Adeline Ruyssen-Witrand1, Arnaud L. Constantin1, Violaine Foltz2, Frédérique Gandjbakhch3 and Alain G. Cantagrel1, 1Rheumatology, Purpan University Hospital, Toulouse, France, 2APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, 3Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France

    Background/Purpose: Ultrasonography (US) can detect synovitis in patients with rheumatoid arthritis (RA) more sensitively than clinical examination either in active disease or in remission.1, 2…
  • Abstract Number: 1011 • 2012 ACR/ARHP Annual Meeting

    Structural Damage Is Reduced by Early Achievement of Clinical Remission

    Paul Emery1, Vibeke Strand2, Andrew S. Koenig3, Ronald Pedersen3 and Eustratios Bananis4, 1Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2Biopharmaceutical Consultant, Portola Valley, CA, 3Specialty Care, Pfizer Inc, Collegeville, PA, 4Specialty Care, Pfizer Inc., Collegeville, PA

    Background/Purpose: The importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent structural damage is established.1 The objective of this…
  • Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting

    Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis

    Ryusuke Yoshimi1, Maasa Hama1, Daiga Kishimoto1, Reikou Watanabe1, Takeaki Uehara2, Yukiko Asami1, Atsushi Ihata1, Atsuhisa Ueda1, Mitsuhiro Takeno1 and Yoshiaki Ishigatsubo1, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan

    Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…
  • Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting

    Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide

    Thomas J. A. Lehman1, Emily Baird2, Anusha Ramanathan3, Risa Alperin3, Emma J. MacDermott3, Alexa B. Adams3, Laura V. Barinstein3 and Lakshmi N. Moorthy4, 1Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, 2Hospital for Special Surgery, NY, 3Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 4Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ

    Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
  • Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting

    Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study 

    J.V. Tovar Beltrán1, M.A. Guzmán Úbeda2, I. Mateo Bernardo3, Rosario García-Vicuña4, M. Rodríguez-Gómez5, M. Belmonte-Serrano6, C. Marras7, E. Loza Cortina8, E. Pérez Pampin9, V. Vila Fayos10, A.B. Romero Silva11 and A. Balsa12, 1Hospital General Universitario de Elche, Alicante, Spain, 2Hospital Universitario Virgen de las Nieves, Granada, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario La Princesa, Madrid, Spain, 5Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 6Hospital General de Castellón, Castellón, Spain, 7Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 8Hospital de Navarra, Navarra, Spain, 9Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 10Hospital Comarcal de Vinaroz, Castellón, Spain, 11Roche Farma, Madrid, Spain, 12Rheumatology, Hospital La Paz, Madrid, Spain

    Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology